卫材“仑卡奈单抗“获FDA批准治疗早期阿尔茨海默病

智通财经网
27 Jan

智通财经APP获悉,1月26日,卫材(ESALY.US)和渤健(BIIB.US)共同宣布仑卡奈单抗(Lecanemab,商品名:Leqembi)静脉注射(IV)制剂的补充生物制品许可申请(sBLA)获得FDA批准,用于每4周1次维持治疗早期阿尔茨海默病(AD)患者,即存在轻度认知障碍或处于轻度痴呆阶段的AD患者。早期AD患者需在起始阶段先接受每两周1次(Q2W)的仑卡奈单抗治疗,然后再接受每月1次...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10